Title of article
The Prevalence and Clinical Significance of Anticardiolipin Antibody in Acute Myeloblastic Leukemia
Author/Authors
Ramzi, M Hematology Research Center - Shiraz University of Medical Sciences, Shiraz , Tahmasebi, J Hematology Research Center - Shiraz University of Medical Sciences, Shiraz , Cohan, N Hematology Research Center - Shiraz University of Medical Sciences, Shiraz , Ayatollahi, M Stem Cell and Transgenic Technology Research Center - Shiraz University of Medical Sciences, Shiraz
Pages
4
From page
564
To page
567
Abstract
Background: Antiphospholipid antibodies, including lupus anticoagulants and anticardiolipin (aCL) antibodies are
associated with a wide variety of disorders including malignancies. The aim of this study was to investigate the prevalence
and prognostic significance of aCL antibodies in Iranian patients with acute myeloblastic leukemia (AML).
Methods: Forty-one patients with AML (27 men and 14 women, mean age 34.9±16.7 years) were included in
this study. aCL IgG and aCL IgM antibodies were evaluated in patients before induction chemotherapy. All patients
were followed up for chemotherapy response.
Results: Antibodies (IgG, IgM or both) were found in 26 of 41 patients (63.4%), of whom 19 (46.3%) had a low
titer, 6 (14.6%) a moderate titer and 1 (2.4%) a high antibody titer. No correlation was found between complete
remission or relapse and aCL antibodies positivity.
Conclusion: aCL antibody titers are slightly to moderately elevated in patients with hematologic malignancies,
and these antibodies do not correlate with disease prognosis
Keywords
Anticardiolipin antibody , Acute myeloblastic leukemia , Clinical significance , Iran
Journal title
Astroparticle Physics
Serial Year
2010
Record number
2441605
Link To Document